Indian Scientists Closer to Treating Non-Alcoholic Fatty Liver Disease

by Dr. Trupti Shirole on  October 3, 2016 at 2:47 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Non-alcoholic fatty liver disease (NAFLD) is the most common liver affliction across the globe. It affects more than 30% adult Indians and occurs when more than 5 to 10% of the liver's weight is fat. There is no definite therapy for the disease.
 Indian Scientists Closer to Treating Non-Alcoholic Fatty Liver Disease
Indian Scientists Closer to Treating Non-Alcoholic Fatty Liver Disease

Advancing the hunt for elusive therapeutics against NAFLD, the Indian researchers have discovered a new mechanism through which the liver hoards up extra fat from sources other than alcohol.

They have also identified a brand new drug target for potential therapy for the disease, that tends to develop in people who are overweight or obese or have type-2 diabetes.

Moreover, a significant number of NAFLD patients progress to the most extreme form of the disease called non-alcoholic steatohepatitis (NASH), an irreversible clinical condition that causes the liver to swell and become damaged and trigger cirrhosis in adults.

The senior researcher Partha Chakrabarti's research group along with Saikat Chakrabarti's laboratory at Indian Institute of Chemical Biology, a unit of CSIR, decided to take a shot at the silent, crippling disease that evolves over decades, its prevalence advantaged with low public awareness.

They literally copped their eyes on to the cell's protein degradation machinery to zero-in on the target protein COP1.

"Multiple molecular mechanisms believed to cause NAFLD have been put forward over the years. However, we identified a hitherto unknown mechanism for the control of liver fat," Chakrabarti, Cell Biology & Physiology Division at the institute told IANS.

"We find that inhibition of COP1 can significantly reduce liver fat in NAFLD. However, it is still not clear whether COP1 can halt disease progression or can prevent NASH. We are currently working in this direction," Chakrabarti added.

The study has been published in the journal Diabetes, from American Diabetes Association (ADA).

According to CSIR-IICB Director Samit Chattopadhyay, the development will motivate the scientific community to come up with new solutions to this global problem and is "geared towards India's goal of delivering translational research outputs to the nation."

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Alcoholic Liver Disease Liver Biopsy Hepatitis A Liver Wilson's Disease Biliary Cirrhosis Milk Thistle Current Treatments for Liver Cancer Fatty Liver Disease: A Growing Health Problem in India Living Donor Liver Transplant: What Are the Risks? 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...